Legacy Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $10.7M | Sell |
66,307
-505
| -0.8% | -$73.4K | 3.54% | 2 |
|
|
2021
Q4 | $9.05M | Sell |
66,812
-420
| -0.6% | -$49.6K | 2.93% | 4 |
|
|
2021
Q3 | $7.25M | Sell |
67,232
-351
| -0.5% | -$40.1K | 2.62% | 5 |
|
|
2021
Q2 | $7.61M | Buy |
67,583
+365
| +0.5% | +$41.1K | 2.72% | 5 |
|
|
2021
Q1 | $7.27M | Buy |
67,218
+5,450
| +9% | +$583K | 2.75% | 7 |
|
|
2020
Q4 | $6.62M | Sell |
61,768
-5,835
| -9% | -$561K | 2.59% | 7 |
|
|
2020
Q3 | $5.92M | Buy |
67,603
+3,135
| +5% | +$295K | 2.4% | 8 |
|
|
2020
Q2 | $6.33M | Buy |
64,468
+432
| +0.7% | +$38K | 2.72% | 6 |
|
|
2020
Q1 | $4.88M | Buy |
64,036
+3,101
| +5% | +$264K | 2.42% | 10 |
|
|
2019
Q4 | $5.39M | Buy |
60,935
+1,100
| +2% | +$91.3K | 2.18% | 8 |
|
|
2019
Q3 | $4.53M | Sell |
59,835
-1,179
| -2% | -$80.8K | 1.98% | 15 |
|
|
2019
Q2 | $4.44M | Buy |
61,014
+1,780
| +3% | +$140K | 1.97% | 14 |
|
|
2019
Q1 | $4.77M | Buy |
59,234
+1,955
| +3% | +$160K | 2.23% | 10 |
|
|
2018
Q4 | $5.28M | Buy |
57,279
+1,325
| +2% | +$117K | 2.8% | 3 |
|
|
2018
Q3 | $5.29M | Sell |
55,954
-2,225
| -4% | -$211K | 2.44% | 8 |
|
|
2018
Q2 | $5.39M | Buy |
58,179
+2,785
| +5% | +$272K | 2.64% | 5 |
|
|
2018
Q1 | $5.24M | Sell |
55,394
-1,930
| -3% | -$212K | 2.63% | 5 |
|
|
2017
Q4 | $5.54M | Sell |
57,324
-1,700
| -3% | -$160K | 2.74% | 5 |
|
|
2017
Q3 | $5.25M | Buy |
59,024
+105
| +0.2% | +$7.99K | 2.76% | 4 |
|
|
2017
Q2 | $4.27M | Buy |
58,919
+2,735
| +5% | +$184K | 2.31% | 8 |
|
|
2017
Q1 | $3.66M | Buy |
56,184
+3,008
| +6% | +$189K | 2.05% | 14 |
|
|
2016
Q4 | $3.33M | Buy |
53,176
+2,825
| +6% | +$172K | 2.02% | 14 |
|
|
2016
Q3 | $3.18M | Buy |
50,351
+1,455
| +3% | +$94.2K | 2% | 15 |
|
|
2016
Q2 | $3.03M | Buy |
48,896
+11,125
| +29% | +$678K | 1.88% | 15 |
|
|
2016
Q1 | $2.16M | Buy |
37,771
+2,365
| +7% | +$132K | 1.39% | 26 |
|
|
2015
Q4 | $2.1M | Sell |
35,406
-2,956
| -8% | -$170K | 1.35% | 28 |
|
|
2015
Q3 | $2.09M | Buy |
38,362
+12,350
| +47% | +$804K | 1.42% | 27 |
|
|
2015
Q2 | $1.75M | Buy |
26,012
+845
| +3% | +$55.2K | 1.14% | 32 |
|
|
2015
Q1 | $1.47M | Sell |
25,167
-318
| -1% | -$19.2K | 0.94% | 41 |
|
|
2014
Q4 | $1.67M | Sell |
25,485
-100
| -0.4% | -$6.3K | 1.07% | 33 |
|
|
2014
Q3 | $1.48M | Sell |
25,585
-198
| -0.8% | -$11K | 0.98% | 37 |
|
|
2014
Q2 | $1.46M | Buy |
25,783
+594
| +2% | +$31.2K | 0.94% | 38 |
|
|
2014
Q1 | $1.29M | Sell |
25,189
-50
| -0.2% | -$2.53K | 0.92% | 39 |
|
|
2013
Q4 | $1.33M | Sell |
25,239
-1,138
| -4% | -$55.9K | 0.95% | 40 |
|
|
2013
Q3 | $1.18M | Sell |
26,377
-494
| -2% | -$21.9K | 0.88% | 46 |
|
|
2013
Q2 | $1.11M | Buy |
+26,871
| New | +$1.18M | 0.85% | 45 |
|
Other funds holding ABBV
Legacy Capital Partners's ABBV Position: Q1 2022 in Review
Legacy Capital Partners reduced its AbbVie (ABBV) stake by 0.76% in Q1 2022, selling an estimated $73.4K and leaving 66,307 shares worth $10.7M. The position accounts for 3.54% of the portfolio, ranked #2.
Legacy Capital Partners first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.
- Legacy Capital Partners held 66,307 shares of AbbVie worth $10.7M as of Q1 2022.
- Legacy Capital Partners sold 505 AbbVie shares in Q1 2022, an estimated $73.4K.
- AbbVie made up 3.54% of Legacy Capital Partners's portfolio in Q1 2022, its #2 holding.
- Legacy Capital Partners first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
- 3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.
Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.